Pathologies at the nexus of blood coagulation and inflammation: Thrombin in hemostasis, cancer, and beyond

Journal of Molecular Medicine

Volumn 91, Issue 11, 2013, Pages 1257-1271

  Danckwardt, Sven ^a,b,d   Hentze, Matthias W ^a,c   Kulozik, Andreas E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Cancer; Coagulation; Hemostasis; Immune system; Inflammation; Invasion; Metastasis; Prognosis; Thrombin (F2); Thrombosis; Trousseau's syndrome

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ANTITHROMBIN; BETA CATENIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CYTOKINE; FIBRIN; FIBRINOGEN; HEPARIN COFACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KALLIKREIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN INHIBITOR; THROMBOMODULIN; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CARCINOGENESIS; CELL PROLIFERATION; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; FIBRIN FORMATION; FIBRINOLYSIS; FIBROBLAST; HEMOSTASIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; JACOBSEN SYNDROME; METASTASIS; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN EXPRESSION; REGENERATION; REVIEW; SEPTICEMIA; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; TUMOR GROWTH; TUMOR MICROENVIRONMENT; VASOCONSTRICTION;

ADAPTIVE IMMUNITY; ANIMALS; GENE EXPRESSION REGULATION; HEMOSTASIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; THROMBIN;

EID: 84888645407     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1074-5     Document Type: Review

References (167)

1. Imokawa Y, Brockes JP (2003) Selective activation of thrombin is a critical determinant for vertebrate lens regeneration. Curr Biol 13:877-881
2. Maden M (2003) Regeneration: every clot has a thrombin lining. Curr Biol 13:R517-R518
3. Rittirsch D, Flierl MA, Ward PA (2008) Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8:776-787
4. Borissoff JI, Spronk HMH, Heeneman S, ten Cate H (2009) Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res 82:392-403
5. Turgeon VL, Houenou LJ (1997) The role of thrombin-like (serine) proteases in the development, plasticity and pathology of the nervous system. Brain Res Rev 25:85-95
6. Nierodzik ML, Karpatkin S (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10:355-362
7. Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239-252
8. Rau JC, Beaulieu LM, Huntington JA, Church FC (2007) Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 5:102-115
9. Esmon CT (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264:4743-4746
10. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L (1992) Maturation of the hemostatic system during childhood. Blood 80:1998-2005
11. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258-264
12. Schenone M, Furie BC, Furie B (2004) The blood coagulation cascade. Curr Opin Hematol 11:272-277
13. Danckwardt S, Hartmann K, Gehring NH, Hentze MW, Kulozik AE (2006) 3′ end processing of the prothrombin mRNA in thrombophilia. Acta Haematol 115:192-197
14. Tanaka KA, Key NS, Levy JH (2009) Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 108:1433-1446
15. Becker RC (2005) Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. Am Heart J 149:S2-S8
16. Subramaniam M, Frenette P, Saffaripour S, Johnson R, Hynes R, Wagner D (1996) Defects in hemostasis in P-selectin-deficient mice. Blood 87:1238-1242
17. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591-594
18. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD (2005) Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocrine Rev 26:1-43
19. Shpacovitch V, Feld M, Hollenberg MD, Luger TA, Steinhoff M (2008) Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol 83:1309-1322
20. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM et al (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12:682-687
21. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA (1986) Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci 83:4533-4537
22. Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, van der Poll T (1996) Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 76:738-742
23. Chen D, Dorling A (2009) Critical roles for thrombin in acute and chronic inflammation. J Thromb Haemost 7:122-126
24. Chan C-P, Chang M-C, Wang Y-J, Chen L-I, Tsai Y-L, Lee J-J, Jia H-W, Jeng J-H (2008) Thrombin activates Ras-CREB/ATF-1 signaling and stimulates c-fos, c-jun, and c-myc expression in human gingival fibroblasts. J Periodont 79:1248-1254
25. Popović M, Smiljanić K, Dobutović B, Syrovets T, Simmet T, Isenović E (2012) Thrombin and vascular inflammation. Mol Cell Biochem 359:301-313
26. Morris R, Winyard PG, Blake DR, Morris CJ (1994) Thrombin in inflammation and healing: relevance to rheumatoid arthritis. Ann Rheum Dis 53:72-79
27. Marty I, Péclat V, Kirdaite G, Salvi R, So A, Busso N (2001) Amelioration of collagen-induced arthritis by thrombin inhibition. J Clin Invest 107:631-640
28. Shin H, Nakajima T, Kitajima I, Shigeta K, Abeyama K, Imamura T, Okano T, Kawahara K, Nakamura T, Maruyama I (1995) Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis. Clin Immunol Immunopathol 76:225-233
29. Ellis CA, Malik AB, Gilchrist A, Hamm H, Sandoval R, Voyno-Yasenetskaya T, Tiruppathi C (1999) Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/mitogen- activated protein kinase pathway. J Biol Chem 274:13718-13727
30. Chapman J (2006) Thrombin in inflammatory brain diseases. Autoimmun Rev 5:528-531
31. Grammas P, Samany PG, Thirumangalakudi L (2006) Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. J Alzheimers Dis 9:51-58
32. Yin X, Wright J, Wall T, Grammas P (2010) Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. Am J Pathol 176:1600-1606
33. Arai T, Miklossy J, Klegeris A, Guo J-P, McGeer PL (2006) Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol 65:19-25
34. Lee KR, Drury I, Vitarbo E, Hoff JT (1997) Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage. J Neurosurg 87:73-78
35. Lee KR, Colon GP, Betz AL, Keep RF, Kim S, Hoff JT (1996) Edema from intracerebral hemorrhage: the role of thrombin. J Neurosurg 84:91-96
36. Kario K, Matsuo T, Hoshide S, Umeda Y, Shimada K (1999) Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. Stroke 30:1033-1037
37. Mhatre M, Nguyen A, Kashani S, Pham T, Adesina A, Grammas P (2004) Thrombin, a mediator of neurotoxicity and memory impairment. Neurobiol Aging 25:783-793
38. Donovan FM, Cunningham DD (1998) Signaling pathways involved in thrombin-induced cell protection. J Biol Chem 273:12746-12752
39. Vaughan P, Pike C, Cotman C, Cunningham D (1995) Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J of Neurosc 15:5389-5401
40. Sun H, Wang X, Degen JL, Ginsburg D (2009) Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 113:1358-1364
41. Mullins ES, Kombrinck KW, Talmage KE, Shaw MA, Witte DP, Ullman JM, Degen SJ, Sun W, Flick MJ, Degen JL (2009) Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Blood 113:696-704
42. Murakami H, Okazaki M, Amagasa H, Oguchi K (2003) Increase in hepatic mRNA expression of coagulant factors in type 2 diabetic model mice. Thromb Res 111:81-87
43. Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, Derian CK, Andrade-Gordon P, Rosen H, Ruf W (2008) Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 452:654-658
44. Li X, Syrovets T, Paskas S, Laumonnier Y, Simmet T (2008) Mature dendritic cells express functional thrombin receptors triggering chemotaxis and CCL18/pulmonary and activation-regulated chemokine induction. J Immunol 181:1215-1223
45. Tracy R (2003) Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. Chest 124:49-57
46. Borissoff JI, Spronk HMH, ten Cate H (2011) The hemostatic system as a modulator of atherosclerosis. N Engl J Med 364:1746-1760
47. Di Nisio M, Middeldorp S, Büller HR (2005) Direct thrombin inhibitors. N Engl J Med 353:1028-1040
48. Ramachandran R, Noorbakhsh F, DeFea K, Hollenberg MD (2012) Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov 11:69-86
49. Members WG, Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H et al (2011) 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction (updating the 2007 guideline). Circulation 123:2022-2060
50. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KAA, Lipka LJ, Liu X, Nicolau JC et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404-1413
51. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary Syndromes. N Engl J Med 366:20-33
52. Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmback K, Xiao Q, Bugge TH, Degen SJ (1998) Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci 95:7597-7602
53. Xue J, Wu Q, Westfield LA, Tuley EA, Lu D, Zhang Q, Shim K, Zheng X, Sadler JE (1998) Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice. Proc Natl Acad Sci 95:7603-7607
54. Sun WY, Coleman MJ, Witte DP, Degen SJF (2002) Rescue of prothrombin-deficiency by transgene expression in mice. Thromb Haemost 88:984-991
55. Zoubine MN, Ma JY, Smirnova IV, Citron BA, Festoff BW (1996) A molecular mechanism for synapse elimination: novel inhibition of locally generated thrombin delays synapse loss in neonatal mouse muscle. Dev Biol 179:447-457
56. Kim S, Buonanno A, Nelson PG (1998) Regulation of prothrombin, thrombin receptor, and protease nexin-1 expression during development and after denervation in muscle. J Neurosci Res 53:304-311
57. Dihanich M, Kaser M, Reinhard E, Cunningham D, Monard D (1991) Prothrombin mRNA is expressed by cells of the nervous system. Neuron 6:575-581
58. Xi G, Reiser G, Keep RF (2003) The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? J Neurochem 84:3-9
59. Riek-Burchardt M, Striggow F, Henrich-Noack P, Reiser G, Reymann KG (2002) Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors. Neurosci Lett 329:181-184
60. Brockes JP, Kumar A (2002) Plasticity and reprogramming of differentiated cells in amphibian regeneration. Nature Rev 3:566-574
61. Grassinger J, Haylock DN, Storan MJ, Haines GO, Williams B, Whitty GA, Vinson AR, Be CL, Li S, Sørensen ES et al (2009) Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with α9β1 and α4β1 integrins. Blood 114:49-59
62. Martin K, Weiss S, Metharom P, Schmeckpeper J, Hynes B, O'Sullivan J, Caplice N (2009) Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin. Circulation Res 105:214-218
63. Tarzami ST, Wang G, Li W, Green L, Singh JP (2006) Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells. J Thromb Haemost 4:656-663
64. Citron BA, Smirnova IV, Arnold PM, Festoff BW (2000) Upregulation of neurotoxic serine proteases, prothrombin, and protease-activated receptor 1 early after spinal cord injury. J Neurotrauma 17:1191-1203
65. Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD (1987) Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest 80:1527-1534
66. Degen JL, Palumbo JS (2012) Hemostatic factors, innate immunity and malignancy. 129. Thromb Res 1:S1-S5, 129 Supplement
67. Green D, Karpatkin S (2010) Role of thrombin as a tumor growth factor. Cell cycle 9:656-661
68. Boccaccio C, Comoglio PM (2005) A functional role for hemostasis in early cancer development. Cancer Res 65:8579-8582
69. Boccaccio C, Comoglio PM (2006) Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6:637-645
70. Franchini M, Mannucci PM (2012) Thrombin and cancer: from molecular basis to therapeutic implications. Semin Thromb Hemost 38:95-101
71. Varki A (2007) Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110:1723-1729
72. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW (1992) Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327:1128-1133
73. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M (1998) Venous thromboembolism and cancer. Lancet 351:1077-1080
74. Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD (2004) Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2:2107-2114
75. Schulman S, Lindmarker P (2000) Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 342:1953-1958
76. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715-722
77. Kuderer NM, Ortel TL, Francis CW (2009) Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 27:4902-4911
78. Petralia GA, Lemoine NR, Kakkar AK (2005) Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2:356-363
79. Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR, Brenner H (2011) Clotting factor gene polymorphisms and colorectal cancer risk. J Clin Oncol 29:1722-1727
80. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL (2002) Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 62:6966-6972
81. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL (2007) Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms. Blood 110:133-141
82. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659
83. Lyman GH, Khorana AA (2009) Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol 27:4821-4826
84. Rickles FR, Patierno S, Fernandez PM (2003) Tissue factor, thrombin, and cancer. Chest 124:58S-68S
85. Ruf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F (2011) Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost 9:306-315
86. Ruf W, Mueller BM (2006) Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32:061-068
87. Palumbo JS (2008) Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost 34:154-160
88. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, Bar-Shavit R (1998) Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4:909-914
89. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120:303-313
90. Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M (2000) Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res 60:6148-6159
91. Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS, D'Andrea MR, Andrade-Gordon P, Karpatkin S (1998) Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 92:3694-3700
92. Nierodzik MLR, Kajumo F, Karpatkin S (1992) Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 52:3267-3272
93. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S (2004) Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 104:2746-2751
94. Wojtukiewicz MZ, Tang DG, Nelson KK, Walz DA, Diglio CA, Honn KV (1992) Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thromb Res 68:233-245
95. Wojtukiewicz MZ, Tang DG, Ciarelli JJ, Nelson KK, Walz DA, Diglio CA, Mammen EF, Honn KV (1993) Thrombin increases the metastatic potential of tumor cells. Int J Cancer 54:793-806
96. Nierodzik MLR, Bain RM, Liu L-X, Shivj i M, Takesh ita K, Karpatki n S (1996) Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumour tyrosine phosphorylation. B J Haematol 92:452-457
97. Klepfish A, Greco MA, Karpatkin S (1993) Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer 53:978-982
98. Zain J, Huang YQ, Feng X, Nierodzik ML, Li JJ, Karpatkin S (2000) Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 95:3133-3138
99. Franchini M, Montagnana M, Targher G, Manzato F, Lippi G (2007) Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombol 24:29-38
100. Möhle R, Green D, Moore MAS, Nachman RL, Rafii S (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci 94:663-668
101. Li J-J, Huang Y-C, Basch R, Karpatkin S (2001) Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 85:204-206
102. Huang Y-Q, Li J-J, Hu L, Lee M, Karpatkin S (2002) Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 99:1646-1650
103. Tsopanoglou NE, Maragoudakis ME (1999) On the mechanism of thrombin-induced angiogenesis: potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J Biol Chem 274:23969-23976
104. Duhamel-Clérin E, Orvain C, Lanza F, Cazenave J-P, Klein-Soyer C (1997) Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells. Arterioscler Thromb Vasc Biol 17:1931-1938
105. Pinedo HM, Verheul HMW, D'Amato RJ, Folkman J (1998) Involvement of platelets in tumour angiogenesis? Lancet 352:1775-1777
106. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirousková M, Degen JL (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178-185
107. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104:397-401
108. Nieswandt B, Hafner M, Echtenacher B, Männel DN (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59:1295-1300
109. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698-3703
110. Danckwardt S, Hartmann K, Katz B, Hentze M, Levy Y, Eichele R, Deutsch V, Kulozik A, Ben-Tal O (2006) The prothrombin 20209 C>T mutation in Jewish-Moroccan Caucasians: molecular analysis of gain-of-function of 3′ end processing. J Thromb Haemost 4:1078-1085
111. Danckwardt S, Kaufmann I, Gentzel M, Foerstner KU, Gantzert AS, Gehring NH, Neu-Yilik G, Bork P, Keller W, Wilm M et al (2007) Splicing factors stimulate polyadenylation via USEs at non-canonical 3′ end formation signals. EMBO J 26:2658-2669
112. Miyawaki Y, Suzuki A, Fujita J, Maki A, Okuyama E, Murata M, Takagi A, Murate T, Kunishima S, Sakai M et al (2012) Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 366:2390-2396
113. Danckwardt S, Gantzert AS, Macher-Goeppinger S, Probst HC, Gentzel M, Wilm M, Grone HJ, Schirmacher P, Hentze MW, Kulozik AE (2011) p38 MAPK controls prothrombin expression by regulated RNA 3′ end processing. Mol Cell 41:298-310
114. Esumi N, Fan D, Fidler IJ (1991) Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 51:4549-4556
115. Nieman MT, LaRusch G, Fang C, Zhou Y, Schmaier AH (2010) Oral thrombostatin FM19 inhibits prostate cancer. Thromb Haemost 104:1044-1048
116. Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KE, Mullins ES, Flick MJ, Queiroz KCS, Shi K, Spek CA et al (2011) Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood 118:2889-2895
117. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518-527
118. Snyder KM, Kessler CM (2008) The pivotal role of thrombin in cancer biology and tumorigenesis. Sem Thromb Hemost 34:734-741
119. Dardik R, Savion N, Kaufmann Y, Varon D (1998) Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIA. Br J Cancer 77:2069-2075
120. Karpatkin S (2004) Does hypercoagulability awaken dormant tumor cells in the host? J Thromb Haemost 12:2103-2106
121. Chen LB, Buchanan JM (1975) Mitogenic activity of blood components. I Thrombin and prothrombin PNAS 72:131-135
122. Gospodarowicz D, Brown KD, Birdwell CR, Zetter BR (1978) Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin. J Cell Biol 77:774-788
123. Carney DH, Stiernberg J, Fenton JW (1984) Initiation of proliferative events by human alpha-thrombin requires both receptor binding and enzymic activity. J Cell Biochem 26:181-195
124. Hu L, Ibrahim S, Liu C, Skaar J, Pagano M, Karpatkin S (2009) Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222. Cancer Res 69:3374-3381
125. Chang M-C, Jeng J-H, Lin C-P, Lan W-H, Tsai W, Hsieh C-C (1999) Thrombin activates the growth, cell-cycle kinetics, and clustering of human dental pulp cells. J Endodont 25:118-122
126. Lockard MM, Witkowski S, Jenkins NT, Spangenburg EE, Obisesan TO (1985) Hagberg JM (2010) Thrombin and exercise similarly influence expression of cell cycle genes in cultured putative endothelial progenitor cells. J Appl Physiol 108:1682-1690
127. Xue YH, Zhang XF, Dong QZ, Sun J, Dai C, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX (2010) Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatol 52:2012-2022
128. Yin Y-J, Salah Z, Grisaru-Granovsky S, Cohen I, Even-Ram SC, Maoz M, Uziely B, Peretz T, Bar-Shavit R (2003) Human protease-activated receptor 1 expression in malignant epithelia. Arterioscl Thromb Vasc Biol 23:940-944
129. Konstantoulaki M, Kouklis P, Malik AB (2003) Protein kinase C modifications of VE-cadherin, p120, and beta-catenin contribute to endothelial barrier dysregulation induced by thrombin. Am J Physiol Lung Cell Mol Physiol 285:L434-L442
130. Radjabi AR, Sawada K, Jagadeeswaran S, Eichbichler A, Kenny HA, Montag A, Bruno K, Lengyel E (2008) Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and1-integrin on the cell surface. J Biol Chem 283:2822-2834
131. Zhang T, Ma Z, Wang R, Wang Y, Wang S, Cheng Z, Xu H, Jin X, Li W, Wang X (2010) Thrombin facilitates invasion of ovarian cancer along peritoneum by inducing monocyte differentiation toward tumor-associated macrophage-like cells. Cancer Immunol Immunother 59:1097-1108
132. Wysoczynski M, Liu R, Kucia M, Drukala J, Ratajczak MZ (2010) Thrombin regulates the metastatic potential of human rhabdomyosarcoma cells: distinct role of PAR1 and PAR3 signaling. Mol Cancer Res 8:677-690
133. Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S, Karpatkin S (2006) Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res 66:4125-4132
134. Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF (1998) In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 275:H1054-H1061
135. Haralabopoulos GC, Grant DS, Kleinman HK, Maragoudakis ME (1997) Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo. Am J Physiol 273:239-245
136. Herbert JM, Dupuy E, Laplace MC, Zini JM, Bar Shavit R, Tobelem G (1994) Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway. Biochem J 303:227-231
137. Hu L, Roth JM, Brooks P, Luty J, Karpatkin S (2008) Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis. Cancer Res 68:4666-4673
138. Hu L, Roth JM, Brooks P, Ibrahim S, Karpatkin S (2008) Twist is required for thrombin-induced tumor angiogenesis and growth. Cancer Res 68:4296-4302
139. Ollivier V, Chabbat J, Herbert JM, Hakim J, de Prost D (2000) Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol 20:1374-1381
140. Rak J, Yu JL, Luyendyk J, Mackman N (2006) Oncogenes, Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 66:10643-10646
141. Boven LA, Vergnolle N, Henry SD, Silva C, Imai Y, Holden J, Warren K, Hollenberg MD, Power C (2003) Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J Immunol 170:2638-2646
142. Ceelie H, Bertina RM, van Hylckama Vlieg A, Rosendaal FR, Vos HL (2001) Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost 85:1066-1070
143. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, Kulozik AE (2001) Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 28:389-392
144. Danckwardt S, Gehring NH, Neu-Yilik G, Hundsdoerfer P, Pforsich M, Frede U, Hentze MW, Kulozik AE (2004) The prothrombin 3′ end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. Blood 104:428-435
145. Soria JM, Almasy L, Souto JC, Tirado I, Borell M, Mateo J, Slifer S, Stone W, Blangero J, Fontcuberta J (2000) Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 95:2780-2785
146. VanLandingham JW, Cekic M, Cutler SM, Hoffman SW, Washington ER, Johnson
147. Levi M, van der Poll T, Büller HR (2004) Bidirectional relation between inflammation and coagulation. Circulation 109:2698-2704
148. Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131:417-430
149. Grosso AR, Martins S, Carmo-Fonseca M (2008) The emerging role of splicing factors in cancer. EMBO rep 9:1087-1093
150. Danckwardt S, Hentze MW, Kulozik AE (2008) 3′ end mRNA processing: molecular mechanisms and implications for health and disease. EMBO J 27:482-498
151. David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24:2343
152. Proudfoot NJ (2011) Ending the message: poly(A) signals then and now. Genes Dev 25:1770-1782
153. Di Giammartino DC, Nishida K, Manley JL (2011) Mechanisms and consequences of alternative polyadenylation. Mol Cell 43:653-866
154. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ (1995) Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270:7420-7426
155. Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9:537-549
156. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883-899
157. Gilbert LA, Hemann MT (2010) DNA damage-mediated induction of a chemoresistant niche. Cell 143:355-366
158. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545
159. Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175-1183
160. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436-444
161. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Brückner UB, Nilsson B, Gebhard F, Lambris JD et al (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185:5628-5636
162. Danckwardt S, Kulozik A (2011) A p38 MAP kinase controlled novel gene regulatory switch links blood coagulation with tumor progression and outcome. Hamostaseologie 1:A75
163. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J (2005) Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 5:45
164. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA (2007) Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7:64
165. Briata P, Forcales SV, Ponassi M, Corte G, Chen CY, Karin M, Puri PL, Gherzi R (2005) p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts. Mol Cell 20:891-903
166. Hoppe B, Dorner T (2012) Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis. Nat Rev Rheumatol 8:738-746
167. Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13:34-45